paclitaxel,olaparib,bevacizumab,carboplatin,durvalumab
roche,merck,astrazeneca
['duo-o', 'ovarian']
interim duo-o data shows survival benefit of immunotherapy in advanced ovarian cancer #asco23 
Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition